Press releases

9 April, 2014

Regulatory

Invitation to the AGM of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting (AGM) of shareholders at 3 p.m. on Friday, 9 May 2014 a ...

31 March, 2014

Regulatory

Increased individual ownership through share exchange from Maas Biolab, LLC

One of NeuroVive's largest shareholders, Maas Biolab, LLC is reducing its ownership by 359,304 shares through a share exchange with its Swedish and US shareholders. This share exchange involves Maas B ...

28 March, 2014

Regulatory

NeuroVive presents significant hepatitis B data for its drug candidate NVP018

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to c ...

25 March, 2014

Regulatory

NeuroVive Pharmaceutical and A1M Pharma initiate research collaboration

NeuroVive Pharmaceutical AB (publ) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a co ...

10 March, 2014

Regulatory

NeuroVive starts collaboration to evaluate IPO of subsidiary in Taiwan

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is reporting that the company's subsidiary NeuroVive Pharmaceutical Asia Ltd., whose registered office is in Hong Kong, ha ...

17 February, 2014

Regulatory

NeuroVive treats final patient in European phase III trial on CicloMulsion®

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has reported that the last of a total of 972 patients have now been enrolled and treated in its ongoing European phase III ...

29 January, 2014

Regulatory

NeuroVive extends partnership agreement with InVentiv Health to prepare for upcoming market launch

Agreement expands consulting services acquired by NeuroVive, with the possibility of a broader partnership for development and commercialization services.

23 January, 2014

Regulatory

Supplementary subscription undertakings by transfer of subscription rights

One of NeuroVive's largest shareholders, Baulos Capital (formerly Private Placement Sprl) and Dr. Guo Weicheng, co-founder of Sihuan Pharmaceuticals (the company's partner in China) have undertaken to ...

22 January, 2014

Regulatory

Last day of trading in subscription rights in the ongoing rights issue

NeuroVive Pharmaceutical AB (publ) today announced that 22 January 2014 is the last day of trading in subscription rights in the company's ongoing new issue. The subscription period will continue unti ...

13 December, 2013

Regulatory

Report from Extraordinary General Meeting

On 13 December, NeuroVive Pharmaceutical AB (publ) held an Extraordinary General Meeting (EGM), whose resolutions are summarized in what follows. All resolutions were reached with the requisite majori ...

12 June, 2013

Regulatory

NeuroVive signs collaboration agreement with Isomerase Therapeutics and receives the first milestone payment from Sihuan

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from ...

5 June, 2013

Regulatory

First patient recruited to clinical phase II study for treatment of traumatic brain injury

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company ́s drug candidate NeuroSTAT® for the ...